Witryna4 lut 2024 · LOS ANGELES, Feb. 4, 2024 — Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b /2a clinical trial testing Imx-110 in patients with refractory solid tumors. To-date, the trial has accrued patients across tumor types. The expansion of the study to the US builds … Witryna23 mar 2024 · LOS ANGELES, March 23, 2024 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate – cardiac, renal, …

ImmixBio Management Answers Top-Voted Investor Questions at …

Witryna10 sty 2024 · Immix Biopharma, Inc. is a privately held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The team was founded … WitrynaLOS ANGELES, March 10, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific … rcfe administrator license search

ImmixBio IMX-110 Produced 50% Positive Response Rate in

WitrynaImmix Biopharma, Inc - Tissue-Specific Therapeutics (TSTx) Targeting Oncology & Immuno-Dysregulated Diseases Witryna19 sty 2024 · Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by … Witryna19 gru 2024 · Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our proprietary SMARxT Tissue-Specific™ Platform produces drug candidates that circulate in the … rcfe 624